Holmström M, Bratt G, Törnebohm E, Rhedin A S, Lockner D
Department of Medicine, Huddinge University Hospital, Sweden.
J Intern Med. 1990 Dec;228(6):647-9. doi: 10.1111/j.1365-2796.1990.tb00293.x.
During the last 10 years, four of 150 (2.7%) patients with deep venous thrombosis (DVT) treated with streptokinase (SK) at our department have died of pulmonary embolism (PE). A retrospective study of 1393 DVT patients treated with heparin during the period 1973-1986 showed that five (0.36%) of these patients died of PE while still on heparin. In this paper we describe the four patients treated with SK who developed fatal PE. In our opinion this increase in mortality does not warrant the use of SK in routine treatment of DVT of the leg before a proper trial has been conducted to compare the frequencies of pulmonary embolism after both treatments.
在过去10年里，在我们科室接受链激酶（SK）治疗的150例深静脉血栓形成（DVT）患者中有4例（2.7%）死于肺栓塞（PE）。一项对1973年至1986年期间接受肝素治疗的1393例DVT患者的回顾性研究表明，这些患者中有5例（0.36%）在仍接受肝素治疗时死于PE。在本文中，我们描述了4例接受SK治疗后发生致命性PE的患者。我们认为，在进行适当试验以比较两种治疗后肺栓塞的发生率之前，这种死亡率的增加并不足以证明在腿部DVT的常规治疗中使用SK是合理的。
